TB vaccines; promoting rapid and durable protection in the lung

Current Opinion in Immunology

Volumn 35, Issue , 2015, Pages 55-62

  Andersen, Peter ^a   Urdahl, Kevin B ^b,c  

^a STATENS SERUM INSTITUT   (Denmark)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; GAMMA INTERFERON; L SELECTIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CELL LINEAGE; CLINICAL EFFECTIVENESS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INFECTION CONTROL; LATENT TUBERCULOSIS; MEMORY CELL; MEMORY T LYMPHOCYTE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN LOCALIZATION; REVIEW; TUBERCULOSIS; VACCINE PRODUCTION; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LUNG; METABOLISM; MICROBIOLOGY; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LUNG; MYCOBACTERIUM TUBERCULOSIS; T-LYMPHOCYTES; TUBERCULOSIS; VACCINES;

EID: 84934976847     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.06.001     Document Type: Review

References (55)

1. Glaziou P., Sismanidis C., Floyd K., Raviglione M. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med 2015, 5:a017798.
2. Gagneux S. Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci 2012, 367:850-859.
3. Ernst J.D. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012, 12:581-591.
4. Kagina B.M., Abel B., Scriba T.J., Hughes E.J., Keyser A., Soares A., Gamieldien H., Sidibana M., Hatherill M., Gelderbloem S., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010, 182:1073-1079.
5. Weiner J., Kaufmann S.H. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med 2014, 275:467-480.
6. Frick M. The TB vaccines pipeline: where are we going, where have we been?. The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Immune-based and Gene Therapies and Research Toward the Cure 2013, 263-283. HIV i-Base and Treatment Action Group, New York. A. Benzacar (Ed.).
7. Kaufmann S.H., Lange C., Rao M., Balaji K.N., Lotze M., Schito M., Zumla A.I., Maeurer M. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir Med 2014, 2:301-320.
8. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., Shea J.E., McClain J.B., Hussey G.D., Hanekom W.A., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
9. Beverley P. TB vaccine failure was predictable. Nature 2013, 503:p469.
10. Srivastava S., Ernst J.D., Desvignes L. Beyond macrophages: the diversity of mononuclear cells in tuberculosis. Immunol Rev 2014, 262:179-192.
11. Cambier C.J., Takaki K.K., Larson R.P., Hernandez R.E., Tobin D.M., Urdahl K.B., Cosma C.L., Ramakrishnan L. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature 2014, 505:218-222.
12. Behar S.M., Divangahi M., Remold H.G. Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy?. Nat Rev Microbiol 2010, 8:668-674.
13. Ramakrishnan L. Looking within the zebrafish to understand the tuberculous granuloma. Adv Exp Med Biol 2013, 783:251-266.
14. Shafiani S., Dinh C., Ertelt J.M., Moguche A.O., Siddiqui I., Smigiel K.S., Sharma P., Campbell D.J., Way S.S., Urdahl K.B. Pathogen-specific Treg cells expand early during Mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12. Immunity 2013, 38:1261-1270.
15. Shafiani S., Tucker-Heard G., Kariyone A., Takatsu K., Urdahl K.B. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 2010, 207:1409-1420.
16. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
17. Urdahl K.B. Understanding and overcoming the barriers to T cell mediated immunity against tuberculosis. Semin Immunol 2014, 26:578-587.
18. Gopal R., Rangel-Moreno J., Slight S., Lin Y., Nawar H.F., Fallert Junecko B.A., Reinhart T.A., Kolls J., Randall T.D., Connell T.D., et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol 2013, 6:972-984.
19. Slight S.R., Rangel-Moreno J., Gopal R., Lin Y., Fallert Junecko B.A., Mehra S., Selman M., Becerril-Villanueva E., Baquera-Heredia J., Pavon L., et al. CXCR5+ T helper cells mediate protective immunity against tuberculosis. J Clin Invest 2013.
20. Lindenstrom T., Aagaard C., Christensen D., Agger E.M., Andersen P. High-frequency vaccine-induced CD8(+) T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection. Eur J Immunol 2014, 44:1699-1709.
21. Florido M., Pillay R., Gillis C.M., Xia Y., Turner S.J., Triccas J.A., Stambas J., Britton W.J. Epitope-specific CD4, but not CD8, T-cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection. Eur J Immunol 2014, 45:780-793.
22. Cambier C.J., Falkow S., Ramakrishnan L. Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell 2014, 159:1497-1509.
23. Barry C.E., Boshoff H.I., Dartois V., Dick T., Ehrt S., Flynn J., Schnappinger D., Wilkinson R.J., Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
24. Rogerson B.J., Jung Y.J., LaCourse R., Ryan L., Enright N., North R.J. Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. Immunology 2006, 118:195-201.
25. Bold T.D., Banaei N., Wolf A.J., Ernst J.D. Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of M. tuberculosis in vivo. PLoS Pathog 2011, 7:e1002063.
26. Lindestam Arlehamn C.S., Gerasimova A., Mele F., Henderson R., Swann J., Greenbaum J.A., Kim Y., Sidney J., James E.A., Taplitz R., et al. Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+ CCR6+ Th1 subset. PLoS Pathog 2013, 9:e1003130.
27. Bertholet S., Ireton G.C., Kahn M., Guderian J., Mohamath R., Stride N., Laughlin E.M., Baldwin S.L., Vedvick T.S., Coler R.N., et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol 2008, 181:7948-7957.
28. Aagaard C.S., Hoang T.T., Vingsbo-Lundberg C., Dietrich J., Andersen P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol 2009, 183:2659-2668.
29. Woodworth J.S., Aagaard C.S., Hansen P.R., Cassidy J.P., Agger E.M., Andersen P. Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation. J Immunol 2014, 192:3247-3258.
30. Schenkel J.M., Masopust D. Tissue-resident memory T cells. Immunity 2014, 41:886-897.
31. Sallusto F., Lanzavecchia A., Araki K., Ahmed R. From vaccines to memory and back. Immunity 2010, 33:451-463.
32. Jung Y.J., Ryan L., LaCourse R., North R.J. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2005, 201:1915-1924.
33. Sakai S., Kauffman K.D., Schenkel J.M., McBerry C.C., Mayer-Barber K.D., Masopust D., Barber D.L. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J Immunol 2014, 192:2965-2969.
34. Srivastava S., Ernst J.D. Cutting edge: direct recognition of infected cells by CD4 T cells is required for control of intracellular Mycobacterium tuberculosis in vivo. J Immunol 2013, 191:1016-1020.
35. Reiley W.W., Shafiani S., Wittmer S.T., Tucker-Heard G., Moon J.J., Jenkins M.K., Urdahl K.B., Winslow G.M., Woodland D.L. Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 2010, 107:19408-19413.
36. Lindenstrom T., Knudsen N.P., Agger E.M., Andersen P. Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1-IL-2-secreting central memory cells. J Immunol 2013, 190:6311-6319.
37. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., Rosenkrands I., Andersen P. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009, 182:8047-8055.
38. Hogan R.J., Zhong W., Usherwood E.J., Cookenham T., Roberts A.D., Woodland D.L. Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs. J Exp Med 2001, 193:981-986.
39. Teijaro J.R., Turner D., Pham Q., Wherry E.J., Lefrancois L., Farber D.L. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol 2011, 187:5510-5514.
40. Turner D.L., Bickham K.L., Thome J.J., Kim C.Y., D'Ovidio F., Wherry E.J., Farber D.L. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol 2014, 7:501-510.
41. Turner D.L., Farber D.L. Mucosal resident memory CD4 T cells in protection and immunopathology. Front Immunol 2014, 5:p331.
42. Mackay L.K., Braun A., Macleod B.L., Collins N., Tebartz C., Bedoui S., Carbone F.R., Gebhardt T. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J Immunol 2015, 194:2059-2063.
43. Andersen P., Smedegaard B. CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect Immun 2000, 68:621-629.
44. Moguche A.O., Shafiani S., Clemons C., Larson R.P., Dinh C., Higdon L.E., Cambier C.J., Sissons J.R., Gallegos A.M., Fink P.J., et al. ICOS and Bcl6-dependent pathways maintain a CD4 T cell population with memory-like properties during tuberculosis. J Exp Med 2015, 212:715-728.
45. Ulrichs T., Kosmiadi G.A., Trusov V., Jorg S., Pradl L., Titukhina M., Mishenko V., Gushina N., Kaufmann S.H. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004, 204:217-228.
46. Phuah J.Y., Mattila J.T., Lin P.L., Flynn J.L. Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis. Am J Pathol 2012, 181:508-514.
47. Billeskov R., Christensen J.P., Aagaard C., Andersen P., Dietrich J. Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model. PLoS One 2013, 8:e72185.
48. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V., Beverley P.C., Tchilian E.Z. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181:4955-4964.
49. Jeyanathan M., Damjanovic D., Shaler C.R., Lai R., Wortzman M., Yin C., Zganiacz A., Lichty B.D., Xing Z. Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity. Mucosal Immunol 2013, 6:612-625.
50. Hoang T., Aagaard C., Dietrich J., Cassidy J.P., Dolganov G., Schoolnik G.K., Lundberg C.V., Agger E.M., Andersen P. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS One 2013, 8:e80579.
51. Orr M.T., Beebe E.A., Hudson T.E., Moon J.J., Fox C.B., Reed S.G., Coler R.N. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One 2014, 9:e83884.
52. van Dissel J.T., Joosten S.A., Hoff S.T., Soonawala D., Prins C., Hokey D.A., O'Dee D.M., Graves A., Thierry-Carstensen B., Andreasen L.V., et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 2014, 32:7098-7107.
53. Idoko O.T., Owolabi O.A., Owiafe P.K., Moris P., Odutola A., Bollaerts A., Ogundare E., Jongert E., Demoitie M.A., Ofori-Anyinam O., et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis (Edinb) 2014, 94:564-578.
54. Vogelzang A., Perdomo C., Zedler U., Kuhlmann S., Hurwitz R., Gengenbacher M., Kaufmann S.H. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guerin DeltaureC::hly vaccine's superior protection against tuberculosis. J Infect Dis 2014, 210:1928-1937.
55. Fletcher H.A., Tanner R., Wallis R.S., Meyer J., Manjaly Z.R., Harris S., Satti I., Silver R.F., Hoft D., Kampmann B., et al. Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG. Clin Vaccine Immunol 2013, 20:1683-1689.